Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced Renal Cell Carcinoma~* Must have at least 1 lesion with measurable disease~* Life expectancy of at least 3 months~* Karnofsky Performance Status (KPS) must be =\>70%~Exclusion Criteria:~* Patients/subjects with suspected or known central nervous system metastases unless adequately treated~* Patients/subjects with autoimmune disease~* Patients/subjects who need daily oxygen therapy~Other protocol defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab + Ipilimumab (Type: ACTIVE_COMPARATOR): Nivolumab + Ipilimumab
- Nivolumab + Relatlimab (Type: EXPERIMENTAL): Nivolumab + Relatlimab
- Nivolumab + BMS-986205 (Type: EXPERIMENTAL): Nivolumab + BMS-986205
- Nivolumab + BMS-813160 (Type: EXPERIMENTAL): Nivolumab + BMS-813160 (CCR2/5 dual antagonist)

Based on this trial design, predict the completion outcome and termination type (if applicable).